Can comprehensive echocardiographic evaluation provide an advantage to predict anthracycline-induced cardiomyopathy?

Turk Kardiyoloji Dernegi Arsivi

Volumn 39, Issue 8, 2011, Pages 646-653

  Erdoǧan, Doǧan ^a   Yücel, Habil ^a   Alanoǧlu, Emine Güçhan ^a   Uysal, Bayram Ali ^a   Koçer, Murat ^a   Özaydin, Mehmet ^a   Doǧan, Abdullah ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Anthracyclines adverse effects; Cardiomyopathies; Drug interactions; Echocardiography, doppler; Myocardial contraction; Neoplasms drug therapy; Ventricular function, left

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ADULT; ANTHRACYCLINE INDUCED CARDIOMYOPATHY; ARTICLE; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ARTICLE; CORONARY ARTERY BLOOD FLOW; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PERFORMANCE; HUMAN; LYMPHOMA; MALE; NEOPLASM; PROSPECTIVE STUDY; TISSUE DOPPLER IMAGING; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; ECHOGRAPHY; EVALUATION; MIDDLE AGED; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84861181389     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: 10.5543/tkda.2011.01700     Document Type: Article

References (30)

1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5. (Pubitemid 28446849)
2. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79. (Pubitemid 36605157)
3. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003;97:1991-8. (Pubitemid 36397277)
4. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother 2007;8:1039-58. (Pubitemid 46929299)
5. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79-108. (Pubitemid 43257193)
6. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25-36. (Pubitemid 34049039)
7. Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004;15:1527-34. (Pubitemid 39409744)
8. Kalay N, Başar E, Özdoǧru İ, Er O, Çetinkaya Y, Doǧan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62. (Pubitemid 44855419)
9. Erdoǧan D, Calişkan M, Yildirim İ, Güllü H, Baycan S, Çiftçi O, et al. Effects of normal blood pressure, prehypertension and hypertension on left ventricular diastolic function and aortic elastic properties. Blood Press 2007;16:114-21. (Pubitemid 47050373)
10. Su HM, Lin TH, Voon WC, Lee KT, Chu CS, Lai WT, et al. Differentiation of left ventricular diastolic dysfunction, identification of pseudonormal/ restrictive mitral inflow pattern and determination of left ventricular filling pressure by Tei index obtained from tissue Doppler echocardiography. Echocardiography 2006;23:287-94.
11. Erdoǧan D, Yildirim İ, Çiftçi O, Özer İ, Çalişkan M, GüllüH, et al. Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function. Circulation 2007;115:593-9. (Pubitemid 46226169)
12. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, et al. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009;20:816-27.
13. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79. (Pubitemid 36605157)
14. Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007;50:1435-41. (Pubitemid 47494586)
15. Fumoleau P, Roché H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, et al. Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 2006;17:85-92. (Pubitemid 43033845)
16. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-92. (Pubitemid 32171549)
17. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43.
18. Gulati VK, Katz WE, Follansbee WP, Gorcsan J 3rd. Mitral annular descent velocity by tissue Doppler echocardiography as an index of global left ventricular function. Am J Cardiol 1996;77:979-84. (Pubitemid 26158086)
19. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997;30:474-80.
20. Oki T, Tabata T, Yamada H, Wakatsuki T, Shinohara H, Nishikado A, et al. Clinical application of pulsed Doppler tissue imaging for assessing abnormal left ventricular relaxation. Am J Cardiol 1997;79:921-8. (Pubitemid 27197927)
21. Henein MY, Gibson DG. Long axis function in disease. Heart 1999;81:229-31.
22. Yu CM, Sanderson JE, Marwick TH, Oh JK. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol 2007;49:1903-14. (Pubitemid 46711162)
23. Alam M, Wardell J, Andersson E, Samad BA, Nordlander R. Effects of first myocardial infarction on left ventricular systolic and diastolic function with the use of mitral annular velocity determined by pulsed wave Doppler tissue imaging. J Am Soc Echocardiogr 2000;13:343-52. (Pubitemid 30322432)
24. Sanderson JE. Heart failure with a normal ejection fraction. Heart 2007;93:155-8.
25. Wang M, Yip G, Yu CM, Zhang Q, Zhang Y, Tse D, et al. Independent and incremental prognostic value of early mitral annulus velocity in patients with impaired left ventricular systolic function. J Am Coll Cardiol 2005;45:272-7. (Pubitemid 40094737)
26. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008;97:318-26. (Pubitemid 351725058)
27. Belham M, Kruger A, Mepham S, Faganello G, Pritchard C. Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy. Eur J Heart Fail 2007;9:409-14. (Pubitemid 46441967)
28. Hozumi T, Yoshida K, Akasaka T, Asami Y, Ogata Y, Takagi T, et al. Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography: comparison with invasive technique. J Am Coll Cardiol 1998;32:1251-9. (Pubitemid 28522380)
29. Saraste M, Koskenvuo J, Knuuti J, Toikka J, Laine H, Niemi P, et al. Coronary flow reserve: measurement with transthoracic Doppler echocardiography is reproducible and comparable with positron emission tomography. Clin Physiol 2001;21:114-22.
30. Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186-93. (Pubitemid 34084317)